Uses of Cerberus and derivatives thereof
AssigneeAcceleron Pharma Inc.
InventorsAsya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
Life of this patent
Estimating the term…
Abstract
The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
Claims18
An isolated myostatin antagonist protein comprising an amino acid sequence that has at least 80% identity to the sequence of amino acids 18-241 of human Cerberus (SEQ ID NO:2), wherein said protein comprises a modification with respect to the sequence of amino acids 18-241 of SEQ ID NO:
- 2, such that cleavage in human serum is reduced or eliminated, wherein said protein has myostatin antagonist activity, and wherein said protein is substantially serum stable for a period of at least 24 hours.
An isolated myostatin antagonist protein comprising an amino acid sequence that has at least 90% identity to the sequence of amino acids 162-241 of human Cerberus (SEQ ID NO:2), and wherein at least one cysteine in said protein has been deleted or substituted relative to SEQ ID NO:2.
An isolated myostatin antagonist protein comprising an amino acid sequence that has at least 80% identity to the sequence of amino acids 162-241 of human Cerberus (SEQ ID NO:2), wherein said protein has myostatin antagonist activity, and wherein the protein comprises a modification with respect to the amino acid sequence of SEQ ID NO:2 that reduces or eliminates cleavage within the sequence SHCLPAK (SEQ ID NO:
- 22) of human Cerberus.
Dependencies are inferred from the claim text.